International Recognition Procedure (IRP)
The International Recognition Procedure (IRP) has featured in every one of our newsletters since Fusion Connect went live in 2023 – with IRP being in place since 1st Jan 2024, we felt this newsletter should be no exception! For those wondering why we are still ‘banging on’ about it, the IRP is the final installment […]
InFusion: Membership update
In our last newsletter we introduced you to InFusion, our new membership designed to support Regulatory Affairs Departments and professionals within the UK. Over the past couple of months we have been working hard to develop high quality content for ‘InFusion Graduate‘. I am personally excited about this new offering as I see a real […]
Artificial Intelligence (AI) in Pharma
Artificial Intelligence (AI) isn’t just a concept of the future – it’s a pervasive force shaping our everyday lives. From the personalized recommendations on streaming platforms to the targeted ads that pop up in our social media feeds, AI algorithms silently influence our choices. It powers virtual assistants, streamlines customer service interactions, and optimizes supply […]
Feeling the pain of a medicine shortage – views from a patient and pharma consultant
This is a joint article, written by two of Fusion Pharma’s Senior Regulatory Consultants. The first part is written by Dr Lorraine Marsh from a family impact perspective, followed by Leah Heathman’s view as a regulatory professional having been involved in many medicine shortage resolutions. The words we dread hearing when visiting the pharmacy […]
How Artificial Intelligence is advancing the pharmaceutical industry
Artificial intelligence (AI) has emerged as a game-changer for the pharmaceutical industry, revolutionising drug discovery, development and personalised medicine. With its ability to analyse vast amounts of complex data and patterns in a way we have never been able to do before, AI is facilitating advancements in various aspects of the industry. Drug Discovery One […]
A year in the life of Fusion Pharma
2023 has been an immensely successful year for Fusion Pharma, for which we are very grateful. Our clients have hugely benefited from our experienced and dedicated team, and we have enjoyed building relationships with our new clients. The team has grown and we have expanded our expertise to include Traditional Herbal Medicines. Our website had […]
InFusion Membership is Coming!
The reflection of 2023 is an excellent segue into looking at what 2024 will bring – and in a word it will be ‘InFusion’. InFusion is our new membership designed to support Regulatory Affairs Departments and professionals within the UK. InFusion has been on the cards for several years and our developers are working hard […]
UK Update – International Recognition Procedure and the Windsor Framework
2023 has brought us two further ‘Brexit hangovers’… the International Recognition Procedure (IRP) and the Windsor Framework! Fusion Pharma have been closely monitoring the Medicines and Healthcare products Regulatory Agency (MHRA) guidance, attending key webinars/conferences and working alongside trade associations to feedback challenges to the MHRA in order to update the guidance to alleviate some […]
Vaping – views from a Regulatory Affairs expert… and mother
Has Australia got it right? By prohibiting all varieties of vaping devices, and making them only available on prescription, Australia appears to have gone much further than other countries in combating the uptake of vaping by children. This got me thinking: what should the purpose of vapes be from a healthcare point of view? And […]
International Recognition Procedure
Since leaving the EU, the MHRA has had to adapt to new ways of working with less resource, leading to unprecedented delays in assessment timelines. The International Recognition Procedure (IRP) has been developed to not only replace the soon-to-end ‘Reliance Procedure’, but also to reassure industry about the UK’s place in launching new medicines inline […]